Bioventus Inc. (NASDAQ: BVS) reported Q2 EPS of $0.10, $0.06 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $140.3 million versus the consensus estimate of $138.33 million.

GUIDANCE:

Bioventus Inc. sees FY2022 EPS of $0.47-$0.57, versus the consensus of $0.65. Bioventus Inc. sees FY2022 revenue of $547.5-562.5 million, versus the consensus of $552 million.

For earnings history and earnings-related data on Bioventus Inc. (BVS) click here.